scholarly article | Q13442814 |
P2093 | author name string | McDiarmid SV | |
Ament ME | |||
Busuttil RW | |||
Vargas JH | |||
Goss JA | |||
Martin MG | |||
Younes BS | |||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | immunosuppression | Q1455316 |
P304 | page(s) | 94-99 | |
P577 | publication date | 2000-07-01 | |
P1433 | published in | Transplantation | Q15730500 |
P1476 | title | The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients | |
P478 | volume | 70 |
Q34733329 | Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience |
Q35108227 | Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment |
Q37450543 | Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506) |
Q92608218 | Incidence of Neoplasia in Pigs and Its Relevance to Clinical Organ Xenotransplantation |
Q33870724 | Long-term results of pediatric liver transplantation in a combined pediatric and adult transplant program. |
Q33346685 | Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence |
Q42053532 | Lowered Immune Cell Function in Liver Recipients Recovered From Posttransplant Lymphoproliferative Disease Who Developed Graft Tolerance. |
Q37824825 | Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options |
Q38032320 | Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens |
Q37145738 | Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation. |
Q52739813 | Myasthenia Gravis Complicated with Peripheral T-cell Lymphoma, Not Otherwise Specified (PTCL-NOS), Following Thymectomy and Longstanding Tacrolimus Therapy. |
Q26798306 | Neoplastic disease after liver transplantation: Focus on de novo neoplasms |
Q83364643 | Pediatric liver transplantation |
Q37577733 | Pediatric post-transplant lymphoproliferative disorder after cardiac transplantation |
Q26780262 | Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now? |
Q44170861 | Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience |
Q90449698 | Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder |
Q35147068 | Tacrolimus: a further update of its use in the management of organ transplantation |
Q41219311 | The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder |
Q35045949 | Therapy for acute rejection in pediatric organ transplant recipients |
Q58572650 | Will donor-derived neoplasia be problematic after clinical pig organ or cell xenotransplantation? |
Search more.